S 49076

Drug Profile

S 49076

Alternative Names: S49076

Latest Information Update: 21 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Servier
  • Class Antineoplastics
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto oncogene protein c met inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioblastoma; Non-small cell lung cancer
  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 03 Nov 2016 Servier completes a phase-I/II trial in Glioblastoma (Second-line therapy or greater, Recurrent, Combination therapy, Late-stage disease) in France and Switzerland (PO) (ISRCTN11619481)
  • 14 Apr 2016 Preclinical trials in Hepatocellular carcinoma in France (unspecified route) before April 2016
  • 14 Apr 2016 Pharmacodynamics data from preclinical studies in Hepatocellular carcinoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top